Does UPADACITINIB Cause Skin hypertrophy? 7 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Skin hypertrophy have been filed in association with UPADACITINIB (Rinvoq). This represents 0.0% of all adverse event reports for UPADACITINIB.
7
Reports of Skin hypertrophy with UPADACITINIB
0.0%
of all UPADACITINIB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Skin hypertrophy From UPADACITINIB?
Of the 7 reports, 1 (14.3%) required hospitalization.
Is Skin hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Skin hypertrophy?
DUPILUMAB (149)
SECUKINUMAB (134)
ADALIMUMAB (105)
ETANERCEPT (48)
METHOTREXATE (42)
RITUXIMAB (41)
TACROLIMUS (40)
OMALIZUMAB (35)
PREDNISOLONE (35)
SUNITINIB MALATE (32)
Which UPADACITINIB Alternatives Have Lower Skin hypertrophy Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL